Research Review No. 104.

A new look at treatments for Duchenne Muscular Dystrophy (DMD).

**The Studies:**

These studies (1) from U.S.A. review the current and future treatments of DMD. They start their review by giving a brief outline of the natural history of untreated DMD, which “leads to the loss of independent ambulation by the middle of the patient's second decade, and a fatal outcome due to cardiac or respiratory failure by the third decade.” They then proceed in describing the role of dystrophin and how its absence affects the regeneration of damaged muscle fibres. The authors especially point out that despite the absence of dystrophin from birth the symptoms only begin to be noticed, when the patients have reached 4-8 years of age, coincidental to the depletion of the muscle progenitor cells (MPC).

**References:**